Abstract
The expression of 17β-hydroxysteroid dehydrogenase (17β-HSD) type 1 and type 2 was examined immunohistochemically in 111 invasive ductal carcinomas, and correlated with various clinicopathological parameters. This study investigates local regulatory mechanisms of oestrogens in human breast carcinoma. 17β-HSD type 1 was immunolocalized in carcinoma cells of 68 out of 111 invasive ductal carcinoma cases (61.3%). 17β-HSD type 2 immunoreactivity was not detected in all cases examined. A significant inverse correlation was observed between the immunohistochemical expression of 17β-HSD type 1 and histological grade of the carcinoma (P< 0.02). There was a significant correlation between 17β-HSD type 1 and oestrogen receptor (ER) labelling index (LI) (P< 0.05). In addition, carcinoma cells expressing immunoreactive 17β-HSD type 1 were frequently positive for ER. 17β-HSD type 1 was also correlated with progesterone receptor (PR) LI (P< 0.05). There was a significant inverse correlation between 17β-HSD type 1 and Ki-67 LI (P< 0.0001). No significant correlations were detected between 17β-HSD type 1 and other clinicopathological parameters, including patient age, menopausal status, stage, tumour size, lymph node status and prognosis. This study suggests that 17β-HSD type 1 plays an important role in the regulation of in situ oestradiol production in hormone-dependent breast carcinomas. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Adams EF, Goldham NG and James VTH (1988) Steroidal regulation of oestradiol-17β dehydrogenase activity of the human breast cancer cell line MCF-7. J Endocrinol 118: 149–154
Bloom HJG and Richardson WW (1957) Histological grading and prognosis in breast cancer. A study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 11: 359–377
Bonney RC, Reed MJ, Davison K, Beraneck PA and James VTH (1983) The relationship between 17β-hydroxysteroid dehydrogenase activity and oestrogen concentrations in human breast tumours and in normal breast tissue. Clin Endocrinol 19: 727–739
Brown DC and Gatter KC (1990) Monoclonal antibody Ki-67: its use in histopathology. Histopathology 17: 489–503
Bulun SE and Simpson ER (1994) Regulation of aromatase expression in human tissues. Breast Cancer Res Treat 30: 530–535
Casey ML, MacDonal PC and Andersson S (1994) 17β-hydroxysteroid dehydrogenase type 2* chromosomal assignment and progestin regulation of gene expression in human endometrium. J Clin Invest 94: 2135–2141
Elston CW and Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer. Experience from a large study with long-term follow-up. Histopathology 19: 403–410
Fournier S, Brihmat F, Sterkers N, Martin PM, Kutten F and Mauvais-Jarvis P (1985) Estradiol 17β-hydroxysteroid dehydrogenase, a marker of breast hormone dependency. Cancer Res 45: 2895–2899
Gast MJ, Sims HF, Murdock GL, Gast PM and Strauss AW (1989) Isolation and sequencing of a cDNA clone encoding human placental 17β-estradiol dehydrogenase: identification of the putative cofactor binding site. Am J Obstet Gynecol 161: 1726–1731
Gerdes J, Schwab U, Lemke H and Stein H (1983) Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 31: 13–20
James VHT, Reed MJ and Folkerd EJ (1981) Studies of estrogen metabolism in postmenopausal women with cancer. J Steroid Biochem 15: 235–246
Leszczynski D, Santner SJ, Feil PD and Santen RJ (1988) 17β-hydroxysteroid dehydrogenase in human breast cancer: analysis of kinetic and clinical parameters. Steroids 51: 299–316
Luu-The V, Labrie C, Zhao HF, Couet J, Lachance Y, Simard J, Leblanc G, Cote J, Berube D, Gagne R and Labrie F (1989) Characterization of cDNAs for human estradiol 17β-dehydrogenase and assignment of the gene to chromosome 17: evidence of two mRNA species with distinct 5′-termini in human placenta. Mol Endocrinol 3: 1301–1309
Marrazzo A, La Bara G, Taormina P and Bazan P (1989) Determination of oestrogen receptors with monoclonal antibodies in fine needle aspirates of breast carcinoma. Br J Cancer 59: 426–428
Miettinen MM, Mustonen MVJ, Poutanen MH, Isomaa VV and Vihko RK (1996) Human 17β-hydroxysteroid dehydrogenase type 1 and type 2 isozymes have opposite activities in cultured cells and characteristic cell- and tissue-specific expression. Biochem J 314: 839–845
Miller WR (1991) Aromatase activity in breast tissue. J Steroid Biochem Mol Biol 39: 783–790
Miller WR, Hawkins RA and Forrest AM (1982) Significance of aromatase activity in human breast cancer. Cancer Res 42: 3365–3368
Moghrabi N, Head JR and Andersson S (1997) Cell type-specific expression of 17β-hydroxysteroid dehydrogenase type 2 in human placenta and fetal liver. J Clin Endocrinol Metab 82: 3872–3878
Peltoketo H, Isomaa V, Maentausta O and Vihko R (1988) Complete amino acid sequence of human placental 17β-hydroxysteroid dehydrogenase deduced from cDNA. FEBS Lett 239: 73–77
Pollow K, Boquoi E, Baumann J, Schmidt-Gollwitzer M and Pollow B (1977) Comparison of the in vitro conversion of estradiol-17β to estrone of normal and neoplastic human breast tissue. Mol Cell Endocrinol 6: 333–348
Poutanen M, Isomaa V, Kainulainen K and Vihko R (1990) Progestin induction of 17β-hydroxysteroid dehydrogenase enzyme protein in the T-47D human breast-cancer cell line. Int J Cancer 46: 897–901
Poutanen M, Isomaa V, Lehto VP and Vihko R (1992 a) Immunohistochemical analysis of 17β-hydroxysteroid dehydrogenase in benign and malignant human breast tissue. Int J Cancer 50: 386–390
Poutanen M, Moncharmont B and Vihko R (1992 b) 17β-hydroxysteroid dehydrogenase gene expression in human breast cancer cells: regulation of expression by a progestin. Cancer Res 52: 290–294
Reiner A, Reiner G, Spona J, Schemper M and Holzner JH (1988) Histopathologic characterization of human breast cancer in correlation with estrogen receptor status. Cancer 61: 1149–1154
Rose C, Thorpe SM, Mouridsen HT, Andersen JA, Brincker H and Andersen KW (1983) Anti-oestrogen retreatment of post menopausal women with primary high risk breast cancer. Br Cancer Res Treat 3: 77–84
Rosen PP (1996). Rosen's Breast Pathology. Lippincott-Raven: Philadelphia
Sasano H, Frost AR, Saitoh R, Harada N, Poutanen M, Vihko R, Bulun SE, Silverberg SG and Nagura H (1996) Aromatase and 17β-hydroxysteroid dehydrogenase type 1 in human breast carcinoma. J Clin Endocrinol Metab 81: 4042–4046
Sasano H, Nagura H, Harada N, Goukon Y and Kimura M (1994) Immunolocalization of aromatase and other steroidogenic enzymes in human breast disorders. Hum Pathol 25: 530–535
Suzuki T, Sasano H, Kimura N, Tamura M, Fukaya T, Yajima A and Nagura H (1994) Immunohistochemical distribution of progesterone, androgen and oestrogen receptors in the human ovary during the menstrual cycle: relationship to expression of steroidogenic enzymes. Hum Reprod 9: 1589–1595
Suzuki T, Sasano H, Takaya R, Fukaya T, Yajima A and Nagura H (1998) Cyclic changes of vasculature and vascular phenotypes in normal human ovaries. Hum Reprod 13: 953–959
Takeyama J, Sasano H, Suzuki T, Iinuma K, Nagura H and Andersson S (1998) 17β-hydroxysteroid dehydrogenase type 1 and 2 in human placenta: an immunohistochemical study with correlation to placental development. J Clin Endocrinol Metab 83: 3710–3715
Thomas DB (1984) Do hormones cause cancer?. Cancer 53: 595–604
Veronese SM and Gambacorta M (1991) Detection of Ki-67 proliferation rate in breast cancer. Correlation with clinical and pathologic features. Am J Clin Pathol 95: 30–34
Veronese SM, Gambacorta M, Gottardi O, Scanzi F, Ferrari M and Lampertico P (1993) Proliferation index as a prognostic marker in breast cancer. Cancer 71: 3926–3931
Vihko R and Apter D (1989) Endogenous steroids in the pathophysiology of breast cancer. CRC Crit Rev Oncol/Hematol 9: 1–16
Wu L, Einstein M, Geissler WM, Chan HK, Ellison KO and Andersson S (1993) Expression cloning and characterization of human 17β-hydroxysteroid dehydrogenase type 2, a microsomal enzyme possessing 20α-hydroxysteroid dehydrogenase activity. J Biol Chem 168: 12964–12969
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Suzuki, T., Moriya, T., Ariga, N. et al. 17 β -Hydroxysteroid dehydrogenase type 1 and type 2 in human breast carcinoma: a correlation to clinicopathological parameters. Br J Cancer 82, 518–523 (2000). https://doi.org/10.1054/bjoc.1999.0956
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1054/bjoc.1999.0956
Keywords
This article is cited by
-
In breast cancer subtypes steroid sulfatase (STS) is associated with less aggressive tumour characteristics
British Journal of Cancer (2018)
-
IPET study: an FLT-PET window study to assess the activity of the steroid sulfatase inhibitor irosustat in early breast cancer
Breast Cancer Research and Treatment (2017)
-
Intratumoral Estrogen Concentration and Expression of Estrogen-Induced Genes in Male Breast Carcinoma: Comparison with Female Breast Carcinoma
Hormones and Cancer (2013)
-
Regulation of 17β-hydroxysteroid dehydrogenases in cancer: regulating steroid receptor at pre-receptor stage
Journal of Physiology and Biochemistry (2012)
-
Increased 5α-Reductase Type 2 Expression in Human Breast Carcinoma following Aromatase Inhibitor Therapy: The Correlation with Decreased Tumor Cell Proliferation
Hormones and Cancer (2011)
